Investigational drug · Phase 2
BNT329
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Cancers.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BNT329"
First trial start
2025
Nov 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT329", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Cancers
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT329" as an intervention, largest first.
- A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT07186842 · 245 participants (planned) · Start Nov 18, 2025 · Primary completion May 2030
Drug: BNT329; CA19-9-targeting monoclonal antibody · For: Advanced Solid Cancers
Sites: Denver, Colorado; Orlando, Florida; Detroit, Michigan · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Cancers
- PRL3-ZUMABPhase 34 trials
Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers
- INV-6452Phase 21 trial
Shenzhen Ionova Life Sciences Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.